Title: Cancer patient with terminal prognosis using FenBe
Post by Yadda on Nov 15th, 2025 at 9:53pm
Cancer patient with terminal prognosis ....starts using FenBenFenbendazole is [now] an out of patent veterinary de-worming drug. @04.40 female cancer patient with terminal prognosis starts using FenBen, dosage 222 mg / dayQ.
What was the outcome for this patient ???Dr. John Campbell - FenBen in Stage 4 cancer22 min Nov 10, 2025 https://www.youtube.com/watch?v=X9x02-SB1sk https://www.youtube.com/watch?v=X9x02-SB1sk Dr. John Campbell https://www.youtube.com/@Campbellteaching Quote:
Fenbendazole, inexpensive, widely accessible antiparasitic drug used in veterinary medicine
Patent expired in the early 1990s, making FBZ available as a generic drug
Case 1
An 83-year-old female
October 2021
Stage 4 breast cancer
Initially diagnosed in 2009
Treated 2009, bilateral mastectomy
Recurrence was diagnosed in 2021.
Liver biopsy, confirmed metastatic breast
Ascitic fluid confirmed metastatic breast carcinoma.
Magnetic resonance imaging of the spine, October 2021 metastatic breast cancer, T10, T12, L1, L2, L3, L4, L5, S1, S2, and the iliac bones.
A PET/CT scan on December 29, 2021, showed six hypermetabolic lung lesions
Largest was 2.8 × 1.5 cm
Hypermetabolic liver lesions, 2.9 × 1.7 cm
Hypermetabolic bone lesions, notably a 5.0 × 2.9 cm lytic lesion in L4, extending into the spinal canal, etc
The patient declined further conventional chemotherapy or radiation therapy and was placed under hospice care.
November 22, 2021
Self-administering FBZ daily at a dose of 222 mg.
In December 2021, she received fulvestrant injection, (an estrogen receptor blocker) intended to inhibit cancer growth
January 2022
Targeted radiation for two painful spinal metastases.
These tumors disappeared rapidly, relieving her pain within a few days.
Continued taking 222 mg/day of FBZ for 8 months.
During this time, her liver enzymes normalized
CA 27.29 tumor marker dropped from 316 (November 2021) to 36.6 (July 2022)
April 20, 2022,
PET scan confirmed the absence of any abnormal metabolic activity indicative of cancer.
June 2022
Patient was confirmed to have no evidence of active disease.
All treatments were discontinued, and she was considered to be in complete remission.
Follow-up monitoring was scheduled every 3–6 months.
Throughout her FBZ treatment, she continued her regular supplementation of vitamin D (5,000 IU) and a multivitamin.
Subsequent PET scans showed no abnormal metabolic activity.
The FBZ treatment period revealed no adverse effects at this dosage.
The patient remains recurrence-free and continues to take FBZ daily nearly 3 years after being declared to be in remission.
Joe Tipp’s Protocol
https://www.fenbendazole.org/fenbenda...
Case 2, Prostate cancer, 75 year old man
Bone scans and CT scans, metastases in the spine, pelvic bones, and right humeral head
Conventional treatments
Complementary treatments
The use of FBZ coincided with continued regression of metastatic lesions and sustained undetectable PSA levels
After 26 months of sustained regression and no new progression, the patient remains in near-complete response and continues FBZ with conventional therapy
Case 3, 63-year-old man
Hip growth, melanoma.
PET-CT showed multiple hypermetabolic foci – peritoneal and retroperitoneal nodules, focal uptake in the stomach and small bowel, lesions in the right gluteus medius, quadratus femoris, and L5 vertebra.
Conventional and complementary treatments
The patient remains melanoma recurrence-free over 11 months after being declared to be in remission.
Case Presentations
All three patients, no reported adverse effects
Conclusion
FBZ demonstrates potential as a novel promising therapeutic option for repurposing in oncology.
Its ability to contribute to tumor regression and achieve disease remission warrants further clinical research to establish its efficacy and optimize its use.
|
|
|
ivermectin_fenbend.jpg (132 KB | 2
)